Patients from 22+ countriesPlan your visit →
lutetium-therapy
Considering Lu-177 Therapy · 3 Aug 2026

When PSMA Imaging Is Negative in mCRPC: Lu-177 Eligibility Explained

Your PSA is climbing, but your scans show nothing. Learn why PSMA-PET imaging is the gating test for Lu-177 PSMA therapy, what a negative scan actually means, and what options remain in mCRPC.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 3 Aug 2026
When PSMA Imaging Is Negative in mCRPC: Lu-177 Eligibility Explained

When PSMA Imaging Is Negative in mCRPC: Lu-177 Eligibility Explained

This article is for men with metastatic castration-resistant prostate cancer (mCRPC) - a form of cancer that keeps growing even though you are on hormone therapy. It addresses a question that often comes up: your PSA is rising, but your scans show little or nothing. Can you still get lutetium Lu 177 vipivotide tetraxetan (Pluvicto), or not?

The short answer is that a rising PSA alone is not enough to qualify for Lu-177 PSMA therapy. The treatment requires visible, PSMA-positive disease on a PSMA-PET scan. But there is more to this answer - it's worth understanding before you decide Lu-177 is completely off the table.

What Does PSA-Only Progression Mean in mCRPC?

PSA stands for prostate-specific antigen, a protein made by prostate cells. In mCRPC, doctors track PSA closely because a rising number usually means the cancer is growing. But standard imaging - a CT scan or a bone scan - sometimes shows no new or growing lesions even as the PSA climbs.

Doctors call this biochemical progression, or PSA-only progression. It means the cancer may be growing in places too small for standard imaging to see, or the cancer cells may be changing so they don't show up as well. This happens in mCRPC. The question is: if scans don't show the disease clearly, which treatments might work - including Lu-177 PSMA?

Why the PSMA-PET Scan Is the Gating Test for Lu-177

Lu-177 PSMA therapy works by attaching a radioactive molecule to PSMA - a protein that sits on the surface of prostate cancer cells. Once attached, it delivers targeted radiation directly to those cells. You can read a full explanation of the mechanism in our article on how Lu-177 PSMA works and what theranostics means for metastatic prostate cancer.

The critical point is this: if your cancer cells are not showing up on a PSMA-PET scan, there are two possible explanations. Either the disease is present but too small to detect, or the cancer cells are not expressing enough PSMA protein for the treatment to find them. In either case, the radioligand has no confirmed target. Giving you Lu-177 PSMA therapy without confirmed PSMA-positive disease would mean exposing you to radiation with no proof it would help.

This is why the FDA approved lutetium Lu 177 vipivotide tetraxetan only for patients with PSMA-positive disease confirmed on imaging. Mayo Clinic notes that patients must have a positive PSMA-PET scan as part of the eligibility criteria. A negative or equivocal scan does not meet that standard.

What Does "PSMA-Positive" Actually Mean on a Scan Report?

This detail matters as you review your own imaging report. In the phase 3 VISION trial - the study that led to FDA approval of this therapy - PSMA-positive meant at least one lesion with PSMA uptake higher than the liver, with no lesions that were PSMA-negative. This second part mattered: even one sizable lesion with low PSMA uptake disqualified patients.

The Prostate Cancer Foundation explains how PSMA imaging shaped the VISION trial design, and notes that the FDA has since expanded the approval to allow treatment at an earlier stage in the mCRPC journey - before chemotherapy, for patients who have received at least one androgen receptor pathway inhibitor. But you still need PSMA-positive imaging to get this treatment.

A study presented at ASCO looked at patients screened for the VISION trial who didn't meet imaging criteria but received Lu-177 PSMA anyway. Doctors are still examining where the imaging cutoff should be, but current practice still requires a positive PSMA-PET scan.

Three Reasons Your PSMA Scan May Be Negative When Your PSA Is Rising

If your PSA is climbing but your PSMA-PET scan is negative or very faint, there are several possible explanations.

  • Very small volume disease. PSMA-PET scans are sensitive, but they can miss very small lesions. In early or low-volume disease, cancer may be present but below the size the scanner can reliably detect. PSMA may still be expressed - the tumor is just too small to show up yet.
  • Loss of PSMA expression. PSMA expression can change. Some prostate cancers lose PSMA expression through epigenetic changes - changes to how genes are switched on and off - especially after previous treatments. About 10% of prostate cancers show little or no PSMA expression because of these changes.
  • Neuroendocrine differentiation. A small number of mCRPC cases become a more aggressive form called neuroendocrine prostate cancer. These tumors don't express PSMA and may not make high PSA levels. They need different diagnosis and treatment. An FDG (fluorodeoxyglucose) PET scan, which finds metabolically active cells, might show cancer where PSMA-PET does not.

If you might fall into one of these categories, don't stop pursuing Lu-177 immediately. Instead, figure out which category applies and what your options are.

Can You Repeat the PSMA-PET Scan?

Yes, in some situations. If your scan was done early in disease progression - before enough disease had developed - a repeat scan months later might show what the first one missed. Your oncologist and nuclear-medicine team should make this decision together, based on how quickly your PSA is rising, your overall condition, and your treatment history.

There are also different PSMA tracers. Most centers use gallium-68 PSMA-11. Some centers have access to fluorine-18 PSMA tracers, which may detect cancer at slightly lower PSA levels in some situations. Talk with your nuclear-medicine doctor about whether a different tracer is right for you. You can learn more about what the scan involves in our guide to preparing for your PSMA-PET scan for Lu-177 eligibility.

If PSMA Imaging Is Negative, What Are Your Options?

A negative PSMA-PET scan in mCRPC is not a dead end. It means your cancer may need a different approach than PSMA-targeted radioligand therapy. Talk to your oncology team about these options:

  • FDG PET/CT. If you have PSMA-low or PSMA-negative disease, a fluorodeoxyglucose PET scan might show metabolically active lesions that the PSMA scan missed. This helps your team understand the cancer's biology before choosing your next treatment.
  • Taxane chemotherapy. Depending on which taxanes you've already received, you might have more chemotherapy options - especially if your disease is growing quickly or in many places.
  • Tumor genomic profiling. If you haven't had genomic testing of your tumor or blood, ask for it. Some genetic mutations might make certain targeted drugs useful for your case. Ask your oncologist whether they've done genomic profiling.
  • Clinical trials. Doctors are actively researching PSMA-negative and PSMA-low mCRPC. Trials are testing antibody-drug conjugates, bispecific antibodies, and other new approaches for tumors that don't express PSMA.

Before committing to your next step, ask a specialist to review your imaging and clinical history - especially if your PSMA-PET result was borderline rather than clearly negative. You can request a Lu-177 eligibility review through Art of Healing Cancer, which reviews scans and clinical histories from patients internationally and can help clarify whether a result merits a second look or whether another path is more appropriate.

Our detailed guide on what to do when your PSMA-PET scan comes back negative or very faint covers these pathways in more depth.

Supporting Bone Health While You Plan Next Steps

Men with mCRPC take androgen deprivation therapy (ADT), which lowers testosterone. A common side effect of long-term ADT is weaker bones. While you figure out eligibility, consider a repeat scan, or decide on next treatment, think about supporting your bones. Ask your care team about calcium, vitamin D, and bone-protective prescription drugs. For over-the-counter support, Ayurnomics carries a Joint and Bone range of supplements that some patients use alongside their prescribed treatment.

What PSA-Only Progression Means for Your Lu-177 Path

A rising PSA in mCRPC doesn't mean you automatically qualify for Lu-177 PSMA therapy, but it doesn't automatically disqualify you either. Your PSMA-PET scan results determine eligibility. A clearly positive scan with PSMA-expressing lesions allows you to get this treatment. A negative or borderline scan means the therapy wouldn't have a confirmed target, so you likely need more imaging, a repeat scan later, or a different systemic therapy.

The science of PSMA expression continues to change. Some patients who are ineligible now may become eligible later as their disease changes or after repeat imaging. Keep talking with your oncology team - and get specialist input when needed. This is the most practical step you can take.

When to Talk to Your Doctor

Talk to your oncologist if your PSA has risen on two or more tests in a row and your most recent CT or bone scan doesn't show new lesions. Ask about PSMA-PET scanning, which tracer your center uses, and what imaging criteria your team uses to decide on Lu-177 eligibility. If your PSMA-PET scan came back negative, ask whether you should get an FDG PET scan and tumor genomic profiling.

If you want a specialist review before deciding, you can send your scans for an eligibility assessment through the Lutetium Therapy contact form. If Lu-177 isn't right for you now, the team can help you find which alternatives might work for your case.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Can my PSA be rising even if my PSMA-PET scan shows nothing?

Yes. PSA can rise even when a PSMA-PET scan detects nothing visible. This can happen if the disease is present but below the size threshold the scanner can reliably detect, if the cancer cells have lost PSMA expression over time due to treatment pressure or epigenetic changes, or if the cancer has shifted toward a type that does not produce much PSMA. A rising PSA alone does not confirm that your cancer is PSMA-positive or that you are eligible for Lu-177 PSMA therapy.

What exactly makes a PSMA-PET scan positive for Lu-177 eligibility?

In the phase 3 VISION trial that led to FDA approval, PSMA-positive was defined as at least one lesion with PSMA uptake greater than the uptake seen in the liver, with no measurable lesion showing uptake at or below liver level. Meeting this definition on a qualified PSMA-PET scan is the minimum imaging requirement for lutetium Lu 177 vipivotide tetraxetan (Pluvicto). If your scan shows borderline or mixed results, a second opinion from a theranostics specialist may help clarify your eligibility.

If my PSMA-PET scan is negative today, could it turn positive later?

It is possible, depending on the reason for the negative result. If the scan was done when disease volume was very low, a later scan performed after further PSA rise may detect lesions that were not visible earlier. However, if the cancer cells have genuinely lost PSMA expression through biological change, a repeat scan is unlikely to give a different result. Your oncologist and nuclear-medicine team can advise on whether a repeat scan makes sense based on your PSA trend and clinical history.

What treatment options are available if I do not qualify for Lu-177 PSMA because of a negative scan?

Several options may still be available. These include FDG PET/CT to identify metabolically active lesions the PSMA scan may have missed, taxane chemotherapy if you have not exhausted available options in that class, tumour genomic profiling to identify targetable mutations, and enrollment in clinical trials studying treatments for PSMA-negative or PSMA-low mCRPC. The right next step depends on your full clinical picture, including prior treatments and current organ function. Your oncologist can guide you on which applies.

Should I get a second opinion if my PSMA-PET came back negative or borderline?

Yes, a second opinion on your imaging is worth pursuing - especially if the result was borderline rather than clearly negative. The interpretation of PSMA uptake relative to liver background can vary between readers, and a specialist in theranostics or nuclear oncology may assess the scan differently. Sending your images to a centre with experience in Lu-177 eligibility assessment can help determine whether the result is genuinely disqualifying or whether further evaluation is warranted.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

Lu-177 PSMA Eligibility When PSMA-PET Is Negative | lutetium-therapy